Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | C1R | P00736 | 6/20 | 0.72 |
| ▸ | F7 | P08709 | 4/20 | 0.69 |
| ▸ | F3 | P13726 | 4/20 | 0.69 |
| ▸ | ELANE | P08246 | 3/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 3/20 | 0.55 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | F2 | P00734 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | PLG | P00747 | 1/20 | 0.55 |
| ▸ | KLK1 | P06870 | 1/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.55 |
| ▸ | C1S | P09871 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30884604 | 0.84 | C1R (1.00) | C1RF7F3ELANEALDH1A1 | |
| SCHEMBL915734 | 0.84 | C1R (1.00) | C1RF7F3ELANEALDH1A1 | |
| SCHEMBL914397 | 0.83 | F7 (0.71) | C1RF7F3ELANEALDH1A1 | |
| SCHEMBL913631 | 0.83 | F7 (0.67) | C1RF7F3ELANEALDH1A1 | |
| SCHEMBL272287 | 0.82 | ELANE (0.81) | C1RELANEALDH1A1NPC1RAB9A | |
| SCHEMBL912739 | 0.82 | F7 (0.58) | C1RF7F3ELANE | |
| SCHEMBL7393864 | 0.82 | F7 (1.00) | C1RF7F3ELANEALDH1A1 | |
| SCHEMBL914399 | 0.81 | F7 (0.58) | C1RF7F3ELANEALDH1A1 | |
| SCHEMBL914392 | 0.81 | F7 (0.68) | C1RF7F3ELANEALDH1A1 | |
| SCHEMBL914143 | 0.81 | KDM4E (0.59) | C1RF7F3ELANEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3027594-B1 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2022-08-10 | — | — | EP | disclosed |
| US-20220017478-A1 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2022-01-20 | — | — | US | disclosed |
| US-11180466-B2 | 2-benzoylaminobenzamide derivatives as Bcl-3 inhibitors | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2021-11-23 | — | — | US | disclosed |
| US-20200031787-A1 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | UNIV COLLEGE CARDIFF CONSULTANTS LTD (GB) | 2020-01-30 | — | — | US | disclosed |
| US-10450285-B2 | 2-benzoylaminobenzamide derivatives as Bcl-3 inhibitors | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2019-10-22 | — | — | US | disclosed |
| US-20160185740-A1 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2016-06-30 | — | — | US | disclosed |
| US-6180625-B1 | MODULATING AND NORMALIZING AN IMPAIRED HAEMOSTATIC BALANCE IN A MAMMAL, WHICH METHOD COMPRISES ADMINISTERING AN EFFECTIVE AMOUNT OF NOVEL BENZOXAZIN DERIVATIVES; ANTICOAGULANTS | NOVO NORDISK A/S (DK) | 2001-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180466-B2 | 2-benzoylaminobenzamide derivatives as Bcl-3 inhibitors | BCL3, BCL2, BCL2A1 | C1R 2738/4885F7 4551/4885F3 284/4885 |
| US-20200031787-A1 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | BCL3, BCL2, BCL2A1 | C1R 2738/4885F7 4551/4885F3 284/4885 |
| US-20160185740-A1 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | BCL3, BCL2, BCL2A1 | C1R 2739/4885F7 4513/4885F3 282/4885 |
| US-10450285-B2 | 2-benzoylaminobenzamide derivatives as Bcl-3 inhibitors | BCL3, BCL2, BCL2A1 | C1R 2739/4885F7 4513/4885F3 282/4885 |
| US-20220017478-A1 | 2-BENZOYLAMINOBENZAMIDE DERIVATIVES AS BCL-3 INHIBITORS | BCL3, BCL2, BCL2A1 | C1R 2739/4885F7 4513/4885F3 282/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.